Glycomic Therapeutics Global Market By Product Type, By Application, By Indication, By Action Mode, By Region and Segment Forecast 2024-2033 | Bayer AG, Sanofi SA, Merck KGaA, ICON PLC, Bio Techne Corp.

Overview and Scope
Glycomic therapeutics refers to the development of glycomics-based approaches in the field of therapeutics. Glycome is the complete set of glycans in a cell or organism, which is important for unraveling the complexity of biological systems and their implications for health and disease. Glycan plays important roles in various biological processes, including cell signaling, immune response, and disease development.

Sizing and Forecast
The glycomic therapeutics market size has grown rapidly in recent years. It will grow from $141.31 billion in 2023 to $163.73 billion in 2024 at a compound annual growth rate (CAGR) of 15.9%. The growth in the historic period can be attributed to increased awareness of glycan significance, rise in chronic diseases, drug development for rare diseases, collaborations in glycomics research..

The glycomic therapeutics market size is expected to see rapid growth in the next few years. It will grow to $301.03 billion in 2028 at a compound annual growth rate (CAGR) of 16.4%. The growth in the forecast period can be attributed to expanding knowledge of glycan biology, precision medicine approaches, rising interest in immunotherapy, increased funding for rare diseases research, emergence of glycan biomarkers.. Major trends in the forecast period include expansion of glycomic applications in oncology, glycoengineering for enhanced therapeutic proteins, inclusion of glycomics in immuno-oncology, glycomics in rare and genetic disorders, regulatory considerations for glycomic drugs..

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/glycomic-therapeutics-global-market-report

Segmentation & Regional Insights
The glycomic therapeutics market covered in this report is segmented –
1) By Class: Isolated, Synthetic
2) By Structures: Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins And Heparin Based Glycans, Targeting Glycosphingolipids, Other Structures
3) By Mode Of Action: Inhibits Neuraminidase, Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate, Erythropoietin And Enzyme Replacement Therapy (ERT), Tissue Plasminogen Activator, Inhibits Glucosylceramide Synthase, Interleukin 1, 2 And 3, Beta And Gamma Interferons, Other Mode Of Action
4) By Indications: Thrombosis And Chemoprophylaxis, Anemia, Anti-Adhesive And Anti-Inflammatory, Cataracts, Gaucher’s Disease, Mps-1 And IV, Cancer, Alzheimer’s Disease, Influenza Type A And B, Other Indications

North America was the largest region in the glycomic therapeutics in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glycomic therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11894&type=smp

Major Driver Impacting Market Growth
The increase in the prevalence of diabetes is expected to drive the growth of the glycomic therapeutics market. Diabetes is a chronic medical condition that affects the body’s ability to regulate blood sugar (glucose) levels. In diabetes, alterations in glycans have been observed, which can contribute to insulin resistance and other metabolic abnormalities. Specific glycan patterns serve as biomarkers for diagnosing diabetes, predicting its progression, and monitoring treatment responses. For instance, in May 2023, according to the report published by the National Center for Health Statistics, a U.S.-based government agency that provides statistical information to guide actions and policies to improve the public health of the American people, the percentage of diagnosed diabetes for adults aged 18 and over, United States increased from 9.3% in 2020 to 9.6% in 2021. Therefore, the increase in the prevalence of diabetes is driving the growth of the glycomic therapeutics market.

Key Industry Players
Major companies operating in the glycomic therapeutics market report are F Hoffmann-La Roche Ltd., Bayer AG, Sanofi SA, Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Merck KGaA, ICON plc, Agilent Technologies Inc., AMS Bio, Shimadzu Corporation, Waters Corporation, Bruker Corporation, BioMarin Pharmaceutical Inc., Bio Techne Corp., Promega Corporation, Halozyme Therapeutics Inc., Takara Bio Inc., Vector Laboratories, New England Biolabs Inc., Protalix Biotherapeutics Inc., Genovis AB, Ray Biotech Life Inc., IEC Group, Ludger Ltd, Z Biotech LLC, Alzheon Inc., GlycoMar Limited

The glycomic therapeutics market report table of contents includes:
1. Executive Summary